Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2024)

Immuneering has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $86116.0 for Q4 2024.

  • Quarterly results put Depreciation & Amortization (CF) at $86116.0 for Q4 2024, down 4.05% from a year ago — trailing twelve months through Dec 2024 was $355807.0 (up 10.22% YoY), and the annual figure for FY2025 was $324517.0, down 8.79%.
  • Depreciation & Amortization (CF) for Q4 2024 was $86116.0 at Immuneering, down from $88949.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for IMRX hit a ceiling of $90533.0 in Q2 2024 and a floor of $5656.0 in Q3 2020.
  • Median Depreciation & Amortization (CF) over the past 5 years was $68075.0 (2022), compared with a mean of $52121.7.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 468.33% in 2022 and later decreased 4.05% in 2024.
  • Immuneering's Depreciation & Amortization (CF) stood at $7449.0 in 2020, then surged by 98.89% to $14815.0 in 2021, then skyrocketed by 418.81% to $76862.0 in 2022, then grew by 16.77% to $89754.0 in 2023, then fell by 4.05% to $86116.0 in 2024.
  • The last three reported values for Depreciation & Amortization (CF) were $86116.0 (Q4 2024), $88949.0 (Q3 2024), and $90533.0 (Q2 2024) per Business Quant data.